We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
187 hedge funds and large institutions have $1.91B invested in Esperion Therapeutics in 2018 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 69 increasing their positions, 54 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
28% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 54
20% more capital invested
Capital invested by funds: $1.6B → $1.91B (+$319M)
13% more funds holding
Funds holding: 165 → 187 (+22)
7.25% more ownership
Funds ownership: 92.75% → 100% (+7.2%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
36% less call options, than puts
Call options by funds: $83.1M | Put options by funds: $130M
Holders
187
Holders Change
+22
Holders Change %
+13.33%
% of All Funds
4.29%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.16%
New
40
Increased
69
Reduced
54
Closed
17
Calls
$83.1M
Puts
$130M
Net Calls
-$46.6M
Net Calls Change
-$49.3M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.5M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$28M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$22.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.9M |
Top Sellers
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$20.3M |
| 2 |
Millennium Management
New York
|
-$18.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$15.1M |
| 5 |
Goldman Sachs
New York
|
-$10.5M |
